Arcus Biosciences, Inc. (RCUS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on October 24, 2024, by Arcus Biosciences, Inc. The filing discloses updated clinical data regarding the Company's investigational product, casdatifan, presented to investors on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements.
Material Changes and Clinical Data
The Company disclosed interim analysis data from the 100mg dose expansion cohort of the Phase 1/1b clinical trial ARC-20. The study evaluates casdatifan in patients with metastatic clear cell renal cell carcinoma who progressed on at least two prior lines of therapy (including anti-PD-1 and tyrosine kinase inhibitor therapy).
- Population: 33 patients enrolled; 32 efficacy-evaluable. The cohort was heavily pre-treated (52% received at least three prior lines; 61% had intermediate risk).
- Objective Response Rate (ORR): 34% (95% CI: 16, 50) per RECIST v1.1. This includes 2 responses pending confirmation.
- Confirmed ORR: 25% (8 patients; 95% CI: 12, 43).
- Disease Control Rate: 81% (95% CI: 64, 93).
- Progression-Free Survival: Median not reached.
- Safety Profile: No unexpected safety signals. Grade 3 treatment-emergent adverse events (TEAEs) related to casdatifan occurred in 42% of patients, primarily anemia (36%) and hypoxia (9%). No patients discontinued due to anemia, and no TEAEs were life-threatening or fatal.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or long-term outlook. Management commentary is limited to the presentation of the clinical data, noting the acceptable and manageable safety profile of the 100mg dose. The primary risk highlighted is the clinical nature of the data, which remains from an interim analysis of a Phase 1/1b trial.
Key Facts for Investor Verification
- Verify the full presentation deck posted on the Company's Investors & Media section for additional context on the ARC-20 trial.
- Confirm the status of the 2 responses pending confirmation to understand the final confirmed ORR.
- Monitor future filings for updates on the safety profile, specifically regarding anemia and hypoxia, as Grade 3 events occurred in 42% of patients.
- Check subsequent 10-Q or 10-K filings for financial metrics, as this 8-K contains no financial data.